Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia
Name
Rahman et al_2017_Somatically acquired activation of LMO2 in T-ALL.pdf
Size
2.53 MB
Format
Adobe PDF
Checksum (MD5)
50f9d1ed00b305d88b4485d88315d5bc
Author(s)
Rahman, Sunniyat
Magnussen, Michael
León, Theresa E.
Farah, Nadine
Li, Zhaodong
Alapi, Krisztina Z.
Mitchell, Rachel J.
Naughton, Tom
Fielding, Adele K.
Pizzey, Arnold
Date Issued
September 2016
Journal
Blood
Publisher
American Society of Hematology
Citation
Rahman, Sunniyat, Michael Magnussen, Theresa E. León, Nadine Farah, Zhaodong Li, Brian J. Abraham, Krisztina Z. Alapi, et al. “Activation of the LMO2 Oncogene through a Somatically Acquired Neomorphic Promoter in T-Cell Acute Lymphoblastic Leukemia.” Blood 129, no. 24 (March 7, 2017): 3221–3226.
Version
Author's final manuscript
Abstract
Somatic mutations within noncoding genomic regions that aberrantly activate oncogenes have remained poorly characterized. Here we describe recurrent activating intronic mutations of LMO2, a prominent oncogene in T-cell acute lymphoblastic leukemia (T-ALL). Heterozygous mutations were identified in PF-382 and DU.528 T-ALL cell lines in addition to 3.7% of pediatric (6 of 160) and 5.5% of adult (9 of 163) T-ALL patient samples. The majority of indels harbor putative de novo MYB, ETS1, or RUNX1 consensus binding sites. Analysis of 5′-capped RNA transcripts in mutant cell lines identified the usage of an intermediate promoter site, with consequential monoallelic LMO2 overexpression. CRISPR/Cas9-mediated disruption of the mutant allele in PF-382 cells markedly downregulated LMO2 expression, establishing clear causality between the mutation and oncogene dysregulation. Furthermore, the spectrum of CRISPR/Cas9-derived mutations provides important insights into the interconnected contributions of functional transcription factor binding. Finally, these mutations occur in the same intron as retroviral integration sites in gene therapy–induced T-ALL, suggesting that such events occur at preferential sites in the noncoding genome.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1182/blood-2016-09-742148
